How many "me-too" drugs are enough? The case of physician preferences for specific statins

被引:6
作者
Austin, PC
Mamdani, MM
Juurlink, DN
机构
[1] Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada
[2] Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada
[3] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada
[4] Univ Toronto, Fac Pharm, Toronto, ON, Canada
[5] Sunnybrook & Womens Coll Hlth Sci Ctr, Div Gen Internal Med, Toronto, ON, Canada
[6] Sunnybrook & Womens Coll Hlth Sci Ctr, Div Clin Pharmacol & Toxicol, Toronto, ON, Canada
关键词
cholesterol; drug benefits formulary; health services research; lipids; prescribing practices;
D O I
10.1345/aph.1G654
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: The increasing availability of "me-too" drugs has provided considerable treatment options for clinicians. However, the number of such drugs within a class that are actually used by clinicians has not been well studied. OBJECTIVE: To determine the number of different statins that individual physicians use in practice. METHODS: The Ontario Drug Benefit database was used to identify physicians who issued at least 10 incident statin prescriptions between October 2001 and May 2003 for patients aged 66 years and older. A preferred statin was defined for each physician, and the proportion of each physician's incident prescriptions written for that agent was determined. We then determined the number of different statins required to fill each physician's incident prescribing needs. RESULTS: A total of 3426 physicians wrote 73 571 incident statin prescriptions. The mean percentage of prescriptions written for each physician's preferred statin formulation was 73.7%. Repeat analysis to examine the proportion of prescriptions filled using each physician's top 2 statin formulations found that the average physician wrote the vast majority of his or her incident prescriptions (94.9%) for only 1 or 2 statins. Half of all physicians used, at most, 2 different statins for all incident prescribing, while 91.3% of physicians used, at most, 3 different statins for all of their incident prescribing. CONCLUSIONS: A high proportion of Ontario physicians issued the majority of their incident statin prescriptions for the same statin formulation. Most physicians required, at most, 3 different statins for all incident statin prescribing.
引用
收藏
页码:1047 / 1051
页数:5
相关论文
共 19 条
[1]   Excess in the pharmaceutical industry [J].
Angell, M .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2004, 171 (12) :1451-1453
[2]   Impact of the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22/reversal of atherosclerosis with aggressive lipid lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada [J].
Austin, PC ;
Mamdani, MM .
CIRCULATION, 2005, 112 (09) :1296-1300
[3]   Changes in prescribing patterns following publication of the ALLHAT trial [J].
Austin, PC ;
Mamdani, MM ;
Tu, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (01) :44-45
[4]   Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative study [J].
Austin, PC ;
Mamdani, MM ;
Tu, K ;
Jaakkimainen, L .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (24) :3241-3242
[5]   Safety of statins - Focus on clinical pharmacokinetics and drug interactions [J].
Bellosta, S ;
Paoletti, R ;
Corsini, A .
CIRCULATION, 2004, 109 (23) :50-57
[6]  
*CTR DRUG EV RES, 2004, NDA APP CAL YEARS 19
[7]   The influence of statin characteristics on their safety and tolerability [J].
De Angelis, G .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (10) :945-955
[8]   The economics of follow-on drug research and development - Trends in entry rates and the timing of development [J].
DiMasi, JA ;
Paquette, C .
PHARMACOECONOMICS, 2004, 22 (Suppl 2) :1-14
[9]   National use of postmenopausal hormone therapy - Annual trends and response to recent evidence [J].
Hersh, AL ;
Stefanick, ML ;
Stafford, RS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (01) :47-53
[10]   Rates of hyperkalemia after publication of the randomized aldactone evaluation study [J].
Juurlink, DN ;
Mamdani, MM ;
Lee, DS ;
Kopp, A ;
Austin, PC ;
Laupacis, A ;
Redelmeier, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (06) :543-551